ÂÜÀòÂÒÂ×

Mr. Smith has more than 25 years of legal and compliance experience serving clients in the life science industries.

Mr. Smith joins IO Biotech from Yumanity Therapeutics, Inc., a publicly traded biotechnology company, where he served as Senior Vice President and General Counsel, and helped lead the sale of the company’s neuroscience assets to a global pharmaceutical company and a reverse merger with a privately held oncology immunotherapy company.

Prior to Yumanity, Mr. Smith served as Senior Vice President and General Counsel of Minerva Neurosciences, Inc. (Nasdaq: NERV), where he was responsible for all legal, governance, and compliance matters. Before joining Minerva, Mr. Smith served as General Counsel of Stallergenes Greer plc, a publicly traded, a global biopharmaceutical company focused on allergy immunotherapy products. Previously, Mr. Smith was the Vice President and General Counsel and led the North American legal department for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Earlier in his career, Mr. Smith was a partner at the international law firm of Nixon Peabody LLP.

Mr. Smith received a B.A. from the University of North Carolina – Chapel Hill and his J.D. from Suffolk University Law School.